



EXPRESS MAIL NO. EV334001754 **US**

<b>RESPONSE TO RESTRICTION REQUIREMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket	SMAR-012
	First Named Inventor	C. Tudan et al.
	Application Number	09/835,107
	Filing Date	April 12, 2001
	Group Art Unit	1647
	Examiner Name	B. Bunner
	Title: CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS	

**RECEIVED**  
JUL 01 2003  
TECH CENTER 1600/2900  
#16  
B.G.  
7/16/03

Sir:

This is in response to the Restriction Requirement dated May 5, 2003.

Applicants hereby elect to prosecute the claims of Group I, claims 1-16, with traverse and Species T or SEQ ID. No. 11.

Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 25, 2003

By:   
Bret Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231